Drugs

pp 1–7 | Cite as

Acalabrutinib: First Global Approval

AdisInsight Report

Abstract

Acerta Pharma is developing the Bruton’s tyrosine kinase inhibitor acalabrutinib (Calquence®) for the treatment of various haematological and solid malignancies. The drug has received accelerated approval from the US FDA for the treatment of mantle cell lymphoma based on the results of a phase II study, and phase III trials in mantle cell lymphoma and chronic lymphocytic leukaemia are currently underway. This article summarizes the milestones in the development of acalabrutinib leading to this first approval for mantle cell lymphoma.

Notes

Compliance with Ethical Standards

Funding

The preparation of this review was not supported by any external funding.

Conflict of interest

During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. A. Markham is a contracted employee and S. Dhillon is a salaried employee of Adis/Springer. They are responsible for the article content, and declare no relevant conflicts of interest.

Additional information about this Adis Drug Review can be found at http://www.medengine.com/Redeem/24FCF060581038CF.

References

  1. 1.
    AstraZeneca, Acerta Pharma. Acalabrutinib granted breakthrough therapy designation by US FDA for the treatment of patients with mantle cell lymphoma [media release]. 1 Aug 2017. http://www.acerta-pharma.com.
  2. 2.
    FDA. FDA approves new treatment for adults with mantle cell lymphoma [media release]. 31 Oct 2017. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm583076.htm.
  3. 3.
    Acerta Pharma. Acerta Pharma announces strategic transaction with AstraZeneca [media release]. 17 Dec 2015. http://www.acerta-pharma.com.
  4. 4.
    Harrington BK, Gulrajani M, Covey T, et al. ACP-196 is a second generation inhibitor of bruton tyrosine kinase (BTK) with enhanced target specificity [abstract]. Blood. 2015;126(23):2908.Google Scholar
  5. 5.
    Covey T, Barf T, Gulrajani M, et al. ACP-196: a novel covalent Bruton’s tyrosine kinase (Btk) inhibitor with improved selectivity and in vivo target coverage in chronic lymphocytic leukemia (CLL) patients [abstract no. 2596]. Cancer Res. 2015;75(15 Suppl).Google Scholar
  6. 6.
    Byrd JC, Harrington B, O’Brien S, et al. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):323–32.CrossRefPubMedGoogle Scholar
  7. 7.
    Herman SEM, Montraveta A, Niemann CU, et al. The Bruton Tyrosine Kinase (BTK) inhibitor acalabrutinib demonstrates potent on-target effects and efficacy in two mouse models of chronic lymphocytic leukemia. Clin Cancer Res. 2017;23(11):2831–41.CrossRefPubMedGoogle Scholar
  8. 8.
    Harrington BK, Gardner HL, Izumi R, et al. Preclinical evaluation of the novel BTK inhibitor acalabrutinib in canine models of B-cell non-Hodgkin lymphoma. PLoS ONE. 2016;11(7):e0159607.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    AstraZeneca. CALQUENCE® (acalabrutinib): prescribing information. 2017. https://www.azpicentral.com/calquence/calquence.pdf#page=1. Accessed 2017.
  10. 10.
    Wang M, Rule SA, Zinzani PL, et al. Efficacy and safety of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma in the phase 2 ACE-LY-004 study [abstract no. 155]. In: American Society of Hematology (ASH) 59th Annual Meeting and Exposition. 2017.Google Scholar
  11. 11.
    Awan FT, Schuh A, Brown JR, et al. Acalabrutinib monotherapy in patients with ibrutinib intolerance: results from the phase 1/2 ACE-CL-001 clinical study [abstract]. Blood. 2016;128(22):638.Google Scholar
  12. 12.
    Hillmen P, Schuh A, Eyre TA, et al. Acalabrutinib monotherapy in patients with richter transformation from the phase 1/2 ACE-CL-001 clinical study [abstract]. Blood. 2016;128(22):60.Google Scholar
  13. 13.
    Byrd J, Wierda W, Schuh A, et al. Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated results from the phase 1/2 ACE-CL-001 study [abstract no. 498]. In: American Society of Hematology (ASH) 59th Annual Meeting and Exposition. 2017.Google Scholar
  14. 14.
    Wierda W, Jones J, Furman R, et al. Acalabrutinib, a second-generation bruton tyrosine kinase (BTK) inhibitor, in previously untreated chronic lymphocytic leukemia (CLL) [abstract no. S431]. Haematologica. 2016;101(Suppl 1):151.Google Scholar
  15. 15.
    Woyach J, Awan F, Jianfar M, et al. Acalabrutinib with obinutuzumab in relapsed/refractory and treatment-naive patients with chronic lymphocytic leukemia: the phase 1b/2 ACE-CL-003 study [abstract no. 432]. In: American Society of Hematology (ASH) 59th Annual Meeting and Exposition. 2017.Google Scholar
  16. 16.
    Overman MJ, Lopez CD, Benson AB, et al. A randomized phase 2 study of the Bruton tyrosine kinase (Btk) inhibitor acalabrutinib alone or with pembrolizumab for metastatic pancreatic cancer (mPC) [abstract no. 4130]. J Clin Oncol. 2016;34(15 Suppl).Google Scholar
  17. 17.
    Zhang T, Harrison M, O’Donnell P, et al. Phase 2 study of pembrolizumab alone or combined with acalabrutinib in platinum-refractory metastatic urothelial carcinoma (mUC) [abstract no. 863P]. Ann Oncol. 2017;28(Suppl 5):303–4.Google Scholar
  18. 18.
    Byrd J, Owen R, O’Brien S, et al. Pooled Analysis of Safety Data from Clinical Trials Evaluating Acalabrutinib Monotherapy in Hematologic Malignancies [abstract no. 4326]. In: American Society of Hematology (ASH) 59th Annual Meeting and Exposition. 2017.Google Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2017

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations